In Brief: Urologix
This article was originally published in The Gray Sheet
Executive Summary
Urologix: Submits pre-market approval application to FDA for its T3 targeted transurethral thermo-ablation system. The non-surgical, catheter-based system is intended for treatment of benign prostatic hyperplasia without the use of anesthesia ("The Gray Sheet" July 1, 1996, In Brief)...